Wire · opportunities
Abbott's TactiFlex Duo ablation catheter achieves positive outcomes in complex AF cases
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 7 September 2026 · Fusion42 review
Abbott's investigational TactiFlex Duo ablation catheter demonstrated high effectiveness and safety for treating complex atrial fibrillation cases in a 12-month global study, supporting its FDA approval process following earlier CE marking in Europe.
This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 31 Aug 2026 and 7 Sep 2026.
◆ ◆ The Wire takeaway
Medtech founders working on cardiac ablation devices can now target FDA approval with proven clinical safety and efficacy data from Abbott's TactiFlex Duo, which could open US market access soon. Patients' long-term outcomes are gaining more attention, highlighting the need for devices that demonstrate durable results beyond the procedure day.
◆ Coverage
2 sources · first reported 31 Aug 2026 · latest 7 Sep 2026
◆ Related on Wire
◆ Topics